[Diagnosis and treatment strategies of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antiviral drugs]

Zhonghua Gan Zang Bing Za Zhi. 2020 Oct 20;28(10):827-830. doi: 10.3760/cma.j.cn501113-20200914-00516.
[Article in Chinese]

Abstract

The occult progression of chronic hepatitis C (CHC) is one of the main causes of liver cirrhosis and hepatocellular carcinoma (HCC). Recently, antiviral treatment of CHC has achieved great progress with the advent of direct-acting antiviral drugs (DAA), especially for special populations including advanced liver disease and HCC. However, DAA and HCC-related issues have also become one of the important concerns of current CHC treatment. This article summarizes the recent research progresses made in the diagnosis and treatment of HCV-related HCC.

慢性丙型肝炎(CHC)隐匿进展是导致肝硬化和肝细胞癌(HCC)的主要原因之一。近年来,随着直接抗病毒药物(DAAs)的问世,CHC尤其是特殊人群包括进展期肝病和HCC的抗病毒治疗取得了巨大进展。DAAs和HCC的相关问题也成为目前CHC治疗的重要关注点之一。现就近年来丙型肝炎相关HCC诊治的最新研究进展进行综述。.

Keywords: Chronic hepatitis C; Diagnosis and treatment strategy; Direct-acting antiviral agents; Hepatocellular carcinoma.

MeSH terms

  • Antiviral Agents* / therapeutic use
  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / virology
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / virology
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / virology

Substances

  • Antiviral Agents